临床医药实践
臨床醫藥實踐
림상의약실천
PROCEEDING OF CLINICAL MEDICINE
2015年
2期
89-91
,共3页
王涛%马梁明%朱秋娟%贡蓉%高志林%田卫伟%任瑞瑞%牛燕燕
王濤%馬樑明%硃鞦娟%貢蓉%高誌林%田衛偉%任瑞瑞%牛燕燕
왕도%마량명%주추연%공용%고지림%전위위%임서서%우연연
老年人%急性髓系白血病%诱导%疗效
老年人%急性髓繫白血病%誘導%療效
노년인%급성수계백혈병%유도%료효
eldly patients%acute Myeloid leukeMia%induction%efficacy
目的:比较 CAG 预激方案与 DA 方案对老年急性髓系白血病(AML)的诱导缓解疗效及毒副反应。方法:选择21例老年 AML 患者,在诱导缓解期分别行两种化疗方案治疗,13例行 CAG 预激治疗方案:粒细胞集落刺激因子(G - CSF)200μg/ d,d1- d14,阿克拉霉素(Acla)20 Mg/ d,d1- d4,阿糖胞苷(Ara - C)每12 h 10 Mg/ M2,d1- d14;8例行 DA 方案化疗:柔红霉素(DNR)每日40 Mg/ M2,d1- d3,Ara - C 每日100 Mg/ M2,d1- d7,观察两组的疗效与不良反应。结果:CAG 预激组6例达完全缓解(CR:46%),2例达部分缓解(PR:15%),总有效率61%。DA 化疗组4例达完全缓解(CR:50%),1例达部分缓解(PR:13%),总有效率63%。组间比较差异无统计学意义(P ﹥0.05)。两组主要不良反应为骨髓抑制、感染,CAG 组感染发生率为46%(6/13),DA 组感染发生率为75%(6/8),组间比较差异有统计学意义(P ﹤0.05)。两组间血液学4级毒性反应的发生率差异无统计学意义,DA 组口腔溃疡发生率明显高于 CAG组。结论:CAG 预激方案可有效治疗老年 AML 患者,且不良反应小,感染发生率低。
目的:比較 CAG 預激方案與 DA 方案對老年急性髓繫白血病(AML)的誘導緩解療效及毒副反應。方法:選擇21例老年 AML 患者,在誘導緩解期分彆行兩種化療方案治療,13例行 CAG 預激治療方案:粒細胞集落刺激因子(G - CSF)200μg/ d,d1- d14,阿剋拉黴素(Acla)20 Mg/ d,d1- d4,阿糖胞苷(Ara - C)每12 h 10 Mg/ M2,d1- d14;8例行 DA 方案化療:柔紅黴素(DNR)每日40 Mg/ M2,d1- d3,Ara - C 每日100 Mg/ M2,d1- d7,觀察兩組的療效與不良反應。結果:CAG 預激組6例達完全緩解(CR:46%),2例達部分緩解(PR:15%),總有效率61%。DA 化療組4例達完全緩解(CR:50%),1例達部分緩解(PR:13%),總有效率63%。組間比較差異無統計學意義(P ﹥0.05)。兩組主要不良反應為骨髓抑製、感染,CAG 組感染髮生率為46%(6/13),DA 組感染髮生率為75%(6/8),組間比較差異有統計學意義(P ﹤0.05)。兩組間血液學4級毒性反應的髮生率差異無統計學意義,DA 組口腔潰瘍髮生率明顯高于 CAG組。結論:CAG 預激方案可有效治療老年 AML 患者,且不良反應小,感染髮生率低。
목적:비교 CAG 예격방안여 DA 방안대노년급성수계백혈병(AML)적유도완해료효급독부반응。방법:선택21례노년 AML 환자,재유도완해기분별행량충화료방안치료,13례행 CAG 예격치료방안:립세포집락자격인자(G - CSF)200μg/ d,d1- d14,아극랍매소(Acla)20 Mg/ d,d1- d4,아당포감(Ara - C)매12 h 10 Mg/ M2,d1- d14;8례행 DA 방안화료:유홍매소(DNR)매일40 Mg/ M2,d1- d3,Ara - C 매일100 Mg/ M2,d1- d7,관찰량조적료효여불량반응。결과:CAG 예격조6례체완전완해(CR:46%),2례체부분완해(PR:15%),총유효솔61%。DA 화료조4례체완전완해(CR:50%),1례체부분완해(PR:13%),총유효솔63%。조간비교차이무통계학의의(P ﹥0.05)。량조주요불량반응위골수억제、감염,CAG 조감염발생솔위46%(6/13),DA 조감염발생솔위75%(6/8),조간비교차이유통계학의의(P ﹤0.05)。량조간혈액학4급독성반응적발생솔차이무통계학의의,DA 조구강궤양발생솔명현고우 CAG조。결론:CAG 예격방안가유효치료노년 AML 환자,차불량반응소,감염발생솔저。
Objective:To investigate the efficacy and toxicity of CAG and DA induction cheMotherapy in eldly patients with acute Myeloid leukeMia. Methods:Twenty - one eldly patients with acute Myeloid leukeMia(AML)were divided into CAG groupand DA group. CAG group:Ara - C 10 Mg/ M2 every 12 hours,d1 - d14,aclarubicin 20 Mg/ d on d1 - d4,G - CSF 200μg/ d on d1 - d14;DA group:DNR 40 Mg·M - 2 ·d - 1 ,d1 - d3,Ara - C 100 Mg·M - 2 ·d - 1 ,d1 - d7. Results:The coMplete response(CR)rate was 46%(6 / 13)and the partial response(PR)rate was 15%(2 / 13)in CAG group and the overall re-sponse(OR)rate was 61% . The coMplete response(CR)rate was 50%(4 / 8)and the partial response(PR)rate was 13%(1 / 8)in DA group and the overall response(OR)rate was 63% . There was no statistical difference in two groups(P ﹥ 0. 05). The Main toxicities of these groups were Myelosupression and infection. The infection rate was 46%(6 / 13)in CAG group and the infection rate was 75%(6 / 8)in DA group. There was a statistical difference in two groups(P ﹤ 0. 05). Conclution:CAG regiMen were effective for the eldly patients with acute Myeloid leukeMia. CAG group has low adverse reactions and low infec-tion rate. The treatMent of stratification of individual can treated the eldly patients with acute Myeloid leukeMia.